Lee Chia-Lin, Chen Cheng-Hsu, Wu Ming-Ju, Tsai Shang-Feng
Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung.
Department of Life Science, Tunghai University, Taichung.
Ther Adv Chronic Dis. 2020 Mar 3;11:2040622319898370. doi: 10.1177/2040622319898370. eCollection 2020.
The effect of glucose control, especially variability of glycated hemoglobin (HbA1c), on estimated glomerular filtration rate (eGFR) decline in type 2 diabetes is still debatable.
We used tertiles of coefficient of variation (CV) to determine the variability of HbA1c (HbA1c_CV). Mixed model repeated measures (MMRM) were used to evaluate the annual eGFR decline rate.
In 1383 type 2 diabetic patients, we found the greater the HbA1c_CV, the greater the eGFR decline ( = 0.01, -0.99 in low, -1.73 in mid, and -2.53 ml/min/1.73 m/year in high HbA1c_CV). Regardless of eGFR (⩾60 or <60 ml/min/1.73 m), the same result holds ( = 0.019 and = 0.007, respectively). In subgroup analysis of baseline HbA1c (%) (HbA1c < 7, 7 ⩽ HbA1c < 9, and HbA1c ⩾ 9), tertiles of HbA1c_CV showed similar effects on annual decline of eGFR ( = 0.193, 0.300, 0.182, respectively), although a trend for a steeper decline in renal function in the highest HbA1c_CV tertile was observed for all HbA1c strata, and even for HbA1c < 7%. A similar behavior was observed in patients with macroalbuminuria or normoalbuminuria ( = 0.219, and 0.109, respectively), with a significant trend in those with microalbuminuria ( = 0.019). Even in patients with HbA1c < 7, high HbA1c_CV also predicts rapid eGFR decline. Before macroalbuminuria, minimizing HbA1c_CV also has renal benefit.
HbA1c variability is an independent risk factor for deterioration of renal function. Even with well-controlled HbA1c levels (<7%), patients with high HbA1c_CV still experienced faster eGFR decline. Early minimization of glycemic variability (before macroalbuminuira) can curb deterioration of renal function. Monitoring and lowering of HbA1c_CV is highly recommended for diabetic care.
血糖控制,尤其是糖化血红蛋白(HbA1c)的变异性,对2型糖尿病患者估算肾小球滤过率(eGFR)下降的影响仍存在争议。
我们使用变异系数(CV)的三分位数来确定HbA1c的变异性(HbA1c_CV)。采用混合模型重复测量(MMRM)来评估每年的eGFR下降率。
在1383例2型糖尿病患者中,我们发现HbA1c_CV越高,eGFR下降越明显(P = 0.01,低HbA1c_CV组为-0.99,中HbA1c_CV组为-1.73,高HbA1c_CV组为-2.53 ml/min/1.73m/年)。无论eGFR如何(≥60或<60 ml/min/1.73m),结果均相同(P分别为0.019和0.007)。在基线HbA1c(%)的亚组分析中(HbA1c < 7、7≤HbA1c < 9和HbA1c≥9),HbA1c_CV的三分位数对eGFR的年下降率显示出相似的影响(P分别为0.193、0.300、0.182),尽管在所有HbA1c分层中,甚至在HbA1c < 7%的患者中,均观察到最高HbA1c_CV三分位数组肾功能下降更为明显的趋势。在有大量白蛋白尿或正常白蛋白尿的患者中也观察到类似情况(P分别为0.219和0.109),在有微量白蛋白尿的患者中有显著趋势(P = 0.019)。即使在HbA1c < 7的患者中,高HbA1c_CV也预示着eGFR快速下降。在出现大量白蛋白尿之前,将HbA1c_CV降至最低也对肾脏有益。
HbA1c变异性是肾功能恶化的独立危险因素。即使HbA1c水平控制良好(<7%),高HbA1c_CV的患者仍经历更快的eGFR下降。早期将血糖变异性降至最低(在出现大量白蛋白尿之前)可抑制肾功能恶化。强烈建议在糖尿病护理中监测和降低HbA